Alivus Life Sciences Ltd Financials

Alivus Life Sciences Ltd Financial Statement

Alivus Life Sciences Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars	Dec 2024	Sep 2024	Jun 2024
Revenue	652.30	515.41	594.11
Operating Expense	451.54	372.52	429.13
Net Profit	136.96	95.32	111.48
Net Profit Margin	21.00	18.49	18.76
Earning Per Share	11.18	7.78	9.10
EBIDTA	199.39	140.99	163.74
Effective Tax Rate	23.32	21.16	22.74

Particulars	Dec 2024
Revenue	652.30
Operating Expense	451.54
Net Profit	136.96
Net Profit Margin	21.00
Earning Per Share	11.18
EBIDTA	199.39
Effective Tax Rate	23.32

Alivus Life Sciences Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Total Revenue Annual	2,283.21	2,161.22	2,123.21
Operating Expenses Annual	1,608.97	1,518.93	1,507.15
Operating Profit Annual	686.29	671.25	630.76
Interest Annual	1.55	0.55	27.96
Depreciation	53.45	42.09	37.88
Net Profit Annual	470.89	466.96	418.72
Tax Annual	160.40	161.65	146.20

Particulars	Mar 2024
Total Revenue Annual	2,283.21
Operating Expenses Annual	1,608.97
Operating Profit Annual	686.29
Interest Annual	1.55
Depreciation	53.45
Net Profit Annual	470.89
Tax Annual	160.40

Alivus Life Sciences Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Cash Flow at the Beginning	283.82	512.16	115.60
Cash Flow from Operations	413.52	306.01	597.59
Cash Flow from Investing	-116.48	-146.75	-122.23
Cash Flow from Financing	-279.44	-387.59	-78.80
Cash Flow at the End	301.41	283.82	512.16

Particulars	Mar 2024
Cash Flow at the Beginning	283.82
Cash Flow from Operations	413.52
Cash Flow from Investing	-116.48
Cash Flow from Financing	-279.44
Cash Flow at the End	301.41

Alivus Life Sciences Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
PBDIT Margin (%)	30.06	31.06	29.71
PBIT Margin (%)	27.72	29.11	27.92
PBT Margin (%)	9.84	-23.82	26.92
Net PROFIT Margin (%)	20.62	21.61	19.72
Return On Networth / Equity (%)	21.07	22.28	29.83
Return On Networth /Employed (%)	27.94	29.80	42.20
Return On Assets (%)	20.83	22.04	29.78
Total Debt / Equity (X)	0.01	0.01	TBA
Asset Turnover Ratio (%)	1.01	1.02	1.51

Particulars	Mar 2024
PBDIT Margin (%)	30.06
PBIT Margin (%)	27.72
PBT Margin (%)	9.84
Net PROFIT Margin (%)	20.62
Return On Networth / Equity (%)	21.07
Return On Networth /Employed (%)	27.94
Return On Assets (%)	20.83
Total Debt / Equity (X)	0.01
Asset Turnover Ratio (%)	1.01

Alivus Life Sciences Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Fixed Assets Annual	809.87	792.89	595.03
Total Current Assets Annual	1,916.00	1,850.34	1,764.58
Non Current Assets Annual	934.41	851.81	706.42
Total Shareholders Funds Annual	2,332.32	2,138.21	2,054.31
Total Assets Annual	2,850.41	2,702.15	2,471.01

Particulars	Mar 2024
Fixed Assets Annual	809.87
Total Current Assets Annual	1,916.00
Non Current Assets Annual	934.41
Total Shareholders Funds Annual	2,332.32
Total Assets Annual	2,850.41

Alivus Life Sciences Ltd Earning Calls

No Data Availabe

Dividend Pages

PE Ratio

FAQS on Alivus Life Sciences Ltd Financials

As of Mar 12, 2025, Alivus Life Sciences Ltd has a market capitalization of 9,499.53 Cr. Value Research classifies it as a Mid-Cap company.

Yes, Alivus Life Sciences Ltd is debt-free with a debt-to-equity ratio of 0.01.

In FY 2024 , Alivus Life Sciences Ltd recorded a total revenue of approximately 2,283.21 Cr marking a significant milestone in the company's financial performance.

Alivus Life Sciences Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.3% and 0.0% annually, respectively..

Alivus Life Sciences Ltd's current PE ratio is 20.17.

Alivus Life Sciences Ltd's ROCE averaged 28.3% from the FY ending March 2022 to 2024, with a median of 28.8%. It peaked at 29.2% in March 2023, reflecting strong capital efficiency over the period..

Alivus Life Sciences Ltd's latest EBIT is Rs. 632.84 Cr, surpassing the average EBIT of Rs. 618.30 Cr over the 5 years..